etidronate has been researched along with Osteomalacia in 22 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Osteomalacia: Disorder caused by an interruption of the mineralization of organic bone matrix leading to bone softening, bone pain, and weakness. It is the adult form of rickets resulting from disruption of VITAMIN D; PHOSPHORUS; or CALCIUM homeostasis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to examine bone histomorphometry before and after 2 yr of a double blind trial of etidronate to determine whether etidronate was associated with the development of osteomalacia and to clarify the mechanism of action." | 5.07 | Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis. ( Huffer, WE; Miller, PD; Ott, SM; Watts, NB; Woodson, GC, 1994) |
| "No publications have reported on osteomalacia in patients receiving intermittent cyclical therapy with etidronate (a bisphosphonate) and undergoing long-term hemodialysis (HD)." | 4.02 | Case report: Osteomalacia due to bisphosphonate treatment in a patient on hemodialysis. ( Hatano, M; Hirota, Y; Hoshino, J; Isawa, K; Kitajima, I; Nakamura, M; Sawa, N; Ubara, Y; Yamamoto, S, 2021) |
| "Inhibition of skeletal mineralisation is a well-recognized complication of disodium etidronate therapy that was identified in the earliest studies of its use in osteoporosis and Paget's disease." | 3.70 | Gross vertebral collapse associated with long-term disodium etidronate treatment for pelvic Paget's disease. ( MacGowan, JR; Morris, VH; Pringle, J; Stamp, TC, 2000) |
| " To evaluate the role of bone remodeling and mature osteoblastic function in aluminum-induced neoosteogenesis, we compared the osteogenic effects of aluminum in normal beagles to those in animals with low turnover osteomalacia induced by treatment with etidronate [1-hydroxyethane-1,1-diphosphoric acid (HEBP)]." | 3.68 | Effects of etidronate-mediated suppression of bone remodeling on aluminum-induced de novo bone formation. ( Drezner, MK; Quarles, LD, 1992) |
| "Transiliac bone biopsies carried out on 13 patients with Paget's disease to evaluate the effects of low-dose diphosphonate (disodium etidronate) therapy showed focal osteomalacia in the 9 patients in whom post-therapy specimens were taken through pagetic bone." | 3.67 | Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. ( Boyce, BF; Boyle, IT; Fogelman, I; Johnston, E; Ralston, S; Smith, L, 1984) |
| "By 24 months, renal tubular acidosis was improved and the bone density had normalized." | 1.39 | Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren's syndrome. ( Hirata, S; Inokuchi, N; Mori, H; Okada, Y; Saito, K; Tanaka, Y; Yamamoto, S, 2013) |
| "Osteomalacia is caused by inadequate or delayed mineralization of bone and is treated by correcting the abnormal intake, loss, or metabolism of vitamin D, phosphate, and calcium." | 1.27 | Osteoporosis, osteomalacia, rickets, and Paget's disease. ( Gall, EP; Nugent, CA; Pitt, MJ, 1984) |
| "Histologic proof of renal osteodystrophy had been obtained in all patients." | 1.26 | Bone scintigraphy in renal osteodystrophy. ( de Graaf, P; de Graeff, J; Pauwels, EK; Schicht, IM; te Velde, J, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (54.55) | 18.7374 |
| 1990's | 4 (18.18) | 18.2507 |
| 2000's | 3 (13.64) | 29.6817 |
| 2010's | 2 (9.09) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Hatano, M | 1 |
| Kitajima, I | 1 |
| Yamamoto, S | 2 |
| Nakamura, M | 1 |
| Isawa, K | 1 |
| Hirota, Y | 1 |
| Hoshino, J | 1 |
| Sawa, N | 1 |
| Ubara, Y | 1 |
| Okada, Y | 1 |
| Mori, H | 1 |
| Hirata, S | 1 |
| Saito, K | 1 |
| Inokuchi, N | 1 |
| Tanaka, Y | 1 |
| Hoppé, E | 1 |
| Masson, C | 1 |
| Laffitte, A | 1 |
| Chappard, D | 1 |
| Audran, M | 1 |
| Labinson, P | 1 |
| Taxel, P | 1 |
| Sato, K | 1 |
| Boyce, BF | 1 |
| Smith, L | 1 |
| Fogelman, I | 3 |
| Johnston, E | 1 |
| Ralston, S | 1 |
| Boyle, IT | 1 |
| Smith, ML | 1 |
| Nugent, CA | 1 |
| Gall, EP | 1 |
| Pitt, MJ | 1 |
| Paterson, CR | 1 |
| Feely, J | 1 |
| Evans, RA | 2 |
| Dunstan, CR | 1 |
| Hills, E | 1 |
| Wong, SY | 1 |
| Raisz, LG | 1 |
| Bessent, RG | 1 |
| Gordon, D | 1 |
| Ott, SM | 1 |
| Woodson, GC | 1 |
| Huffer, WE | 1 |
| Miller, PD | 1 |
| Watts, NB | 1 |
| Thomas, T | 1 |
| Lafage, MH | 1 |
| Alexandre, C | 2 |
| Adami, S | 1 |
| Zamberlan, N | 1 |
| MacGowan, JR | 1 |
| Pringle, J | 1 |
| Morris, VH | 1 |
| Stamp, TC | 1 |
| de Graaf, P | 1 |
| Schicht, IM | 1 |
| Pauwels, EK | 1 |
| te Velde, J | 1 |
| de Graeff, J | 1 |
| Chapuy, MC | 1 |
| Meunier, P | 1 |
| Ryckewaert, A | 1 |
| Lemaire, V | 1 |
| Tubiana, M | 1 |
| Quarles, LD | 1 |
| Drezner, MK | 1 |
| Gibbs, CJ | 1 |
| Aaron, JE | 1 |
| Peacock, M | 1 |
2 reviews available for etidronate and Osteomalacia
| Article | Year |
|---|---|
[Drug-induced osteomalacia].
Topics: Anticonvulsants; Etidronic Acid; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematin | 2007 |
Adverse effects of bisphosphonates. A comparative review.
Topics: Acute Kidney Injury; Animals; Diphosphonates; Etidronic Acid; Gastrointestinal Diseases; Humans; Ost | 1996 |
2 trials available for etidronate and Osteomalacia
| Article | Year |
|---|---|
Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis.
Topics: Bone and Bones; Dose-Response Relationship, Drug; Double-Blind Method; Etidronic Acid; Female; Human | 1994 |
Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate.
Topics: Aged; Bone and Bones; Etidronic Acid; Female; Humans; Male; Middle Aged; Minerals; Osteitis Deforman | 1986 |
18 other studies available for etidronate and Osteomalacia
| Article | Year |
|---|---|
Case report: Osteomalacia due to bisphosphonate treatment in a patient on hemodialysis.
Topics: Bone and Bones; Bone Density Conservation Agents; Calcitriol; Cholecalciferol; Etidronic Acid; Human | 2021 |
Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren's syndrome.
Topics: Acidosis, Renal Tubular; Bone Density Conservation Agents; Drug Therapy, Combination; Etidronic Acid | 2013 |
Osteomalacia in a patient with Paget's bone disease treated with long-term etidronate.
Topics: Aged, 80 and over; Alkaline Phosphatase; Biopsy; Bone Density Conservation Agents; Calcification, Ph | 2012 |
Multiple fractures in a woman receiving 24 years of etidronate treatment for Paget's disease.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneo | 2007 |
Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease.
Topics: Aged; Biopsy; Bone and Bones; Bone Resorption; Etidronic Acid; Female; Humans; Male; Middle Aged; Mi | 1984 |
Diphosphonates in the evaluation of metabolic bone disease.
Topics: Bone and Bones; Bone Diseases, Metabolic; Chronic Kidney Disease-Mineral and Bone Disorder; Diphosph | 1982 |
Osteoporosis, osteomalacia, rickets, and Paget's disease.
Topics: Anti-Inflammatory Agents; Calcitonin; Calcium; Diet; Estrogens; Etidronic Acid; Humans; Osteitis Def | 1984 |
Vitamin D metabolites and analogues, diphosphonates, danazol, and bromocriptine.
Topics: Acromegaly; Bromocriptine; Calcitriol; Danazol; Endometriosis; Etidronic Acid; Female; Fibrocystic B | 1983 |
Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget's disease of bone.
Topics: Etidronic Acid; Fractures, Spontaneous; Humans; Male; Middle Aged; Osteitis Deformans; Osteomalacia; | 1983 |
Disodium etidronate (EHDP)
Topics: Etidronic Acid; Fractures, Spontaneous; Humans; Osteitis Deformans; Osteomalacia | 1984 |
New diphosphonates to block bone resorption.
Topics: Animals; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Double-Blind Method; Eti | 1980 |
A critical assessment of bone scan quantitation (bone to soft tissue ratios) in the diagnosis of metabolic bone disease.
Topics: Adult; Aged; Aging; Bone and Bones; Bone Diseases, Metabolic; Chronic Kidney Disease-Mineral and Bon | 1981 |
Atypical osteomalacia after 2 year etidronate intermittent cyclic administration in osteoporosis.
Topics: Aged; Bone Density; Drug Administration Schedule; Etidronic Acid; Female; Humans; Osteomalacia; Oste | 1995 |
Gross vertebral collapse associated with long-term disodium etidronate treatment for pelvic Paget's disease.
Topics: Aged; Alkaline Phosphatase; Anti-Inflammatory Agents; Arthralgia; Diphosphonates; Etidronic Acid; Fo | 2000 |
Bone scintigraphy in renal osteodystrophy.
Topics: Adolescent; Adult; Alkaline Phosphatase; Bone and Bones; Chronic Kidney Disease-Mineral and Bone Dis | 1978 |
[The hypocalcemia test, using human and salmon synthetic calcitonins. Paradoxical hypercalcemic responses. Responses in patients with Paget's disease treated with EHDP].
Topics: Calcitonin; Calcium; Dose-Response Relationship, Drug; Etidronic Acid; Hormones; Humans; Hyperparath | 1979 |
[Non-hormonal drug treatment in Paget's disease].
Topics: Alkaline Phosphatase; Etidronic Acid; Humans; Hydroxyproline; Organophosphorus Compounds; Osteitis D | 1975 |
Effects of etidronate-mediated suppression of bone remodeling on aluminum-induced de novo bone formation.
Topics: Aluminum; Aluminum Chloride; Aluminum Compounds; Animals; Bone and Bones; Bone Development; Bone Rem | 1992 |